<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590771</url>
  </required_header>
  <id_info>
    <org_study_id>0431-253</org_study_id>
    <nct_id>NCT01590771</nct_id>
  </id_info>
  <brief_title>A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy, Alone or in Combination With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare safety and efficacy of sitagliptin and placebo therapy when added to
      stable sulfonylurea alone or in combination with metformin in participants with type 2
      diabetes mellitus (T2DM). The primary hypothesis of this study is that after 24 weeks, the
      addition of sitagliptin compared with placebo provides greater reduction in hemoglobin A1C
      (HbA1C) in T2DM participants on sulfonylurea alone or in combination with metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2012</start_date>
  <completion_date type="Actual">June 24, 2014</completion_date>
  <primary_completion_date type="Actual">June 10, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced an Adverse Event</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">498</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg oral tablet once daily for 24 weeks</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia®</other_name>
    <other_name>MK-0431</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to sitagliptin oral tablet once daily for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
    <description>Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has T2DM

          -  is currently on a stable regimen of gliclazide or glimepiride, either alone or in
             combination with metformin for ≥ 10 weeks

          -  has a Visit 1/Screening HbA1C between 7.5% and 11.0%

          -  is a male, or a female who is highly unlikely to conceive during the study and for 14
             days after the last dose of study medication

        Exclusion Criteria:

          -  has a history of type 1 diabetes mellitus or a history of ketoacidosis

          -  has been treated with any antihyperglycemic therapies other than a sulfonylurea (alone
             or with metformin) within the prior 12 weeks or has ever

        been treated with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 mimetic
        or analogue

          -  has a history of intolerance or hypersensitivity, or has any contraindication to
             sitagliptin, gliclazide/glimepiride, or metformin

          -  is on a weight loss program and not in the maintenance phase, or has started a weight
             loss medication or has undergone bariatric surgery within 12 months

          -  has undergone a surgical procedure within 4 weeks or has planned major surgery during
             the study

          -  has a medical history of active liver disease

          -  has had new or worsening signs or symptoms of coronary heart disease within the past 3
             months, or has acute coronary syndrome, coronary artery intervention, or stroke or
             transient ischemic neurological disorder

          -  has a diagnosis of congestive heart failure with New York Heart Association Class III
             - IV cardiac status

          -  has a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 90 mmHg

          -  has human immunodeficiency virus (HIV)

          -  has severe peripheral vascular disease

          -  is currently being treated for hyperthyroidism or is on thyroid hormone therapy and
             has not been on a stable dose for at least 6 weeks

          -  has a history of malignancy ≤ 5 years before the study, except for adequately treated
             basal cell or squamous cell skin cancer, or in situ cervical cancer

          -  has a clinically important hematological disorder (such as aplastic anemia,

        myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

          -  is pregnant or breast feeding, or is expecting to conceive or donate eggs during the
             study, including 14 days after the last dose of study medication

          -  is a user of recreational or illicit drugs or has had a recent history of drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <results_reference>
    <citation>Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, Xu L, Hanson ME, Engel SS, Shankar RR. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes. 2017 Jul;9(7):667-676. doi: 10.1111/1753-0407.12456. Epub 2016 Sep 13.</citation>
    <PMID>27502307</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <results_first_submitted>April 16, 2015</results_first_submitted>
  <results_first_submitted_qc>April 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2015</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0431-253&amp;kw=0431-253&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants randomized population.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="249"/>
            <count group_id="B3" value="498"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="9.5"/>
                    <measurement group_id="B2" value="56.5" spread="9.3"/>
                    <measurement group_id="B3" value="57.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (A1C)</title>
          <units>Percent of glycosylated hemoglobin (A1C)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.61" spread="1.06"/>
                    <measurement group_id="B2" value="8.48" spread="0.91"/>
                    <measurement group_id="B3" value="8.55" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour post meal glucose (2-hr PMG)</title>
          <description>Sitagliptin, n=248; placebo, n=249; total, n=497</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="296.5" spread="68.0"/>
                    <measurement group_id="B2" value="290.2" spread="72.4"/>
                    <measurement group_id="B3" value="293.4" spread="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (FPG)</title>
          <description>Sitagliptin, n=249; placebo, n=249; total, n=498</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181.5" spread="40.9"/>
                    <measurement group_id="B2" value="179.8" spread="40.7"/>
                    <measurement group_id="B3" value="180.6" spread="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</title>
        <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</title>
          <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
          <population>Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>Percent of glycosylated hemoglobin (A1C)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" lower_limit="-0.99" upper_limit="-0.76"/>
                    <measurement group_id="O2" value="-0.27" lower_limit="-0.38" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The ANCOVA model controlled for treatment, metformin strata (on or not on metformin), and baseline A1C value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Robust regression</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
            <estimate_desc>Based on robust regression using M-estimation with terms for treatment, metformin strata (on or not on metformin), and baseline A1C value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</title>
        <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</title>
          <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
          <population>Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.7" lower_limit="-49.4" upper_limit="-31.9"/>
                    <measurement group_id="O2" value="-7.7" lower_limit="-16.6" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The ANCOVA model controlled for treatment, metformin strata (on or not on metformin), and baseline 2-hr PMG value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-32.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.4</ci_lower_limit>
            <ci_upper_limit>-20.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</title>
        <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin</title>
          <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
          <population>Full analysis set consists of all participants who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.4" spread="-29.1" lower_limit="-29.1" upper_limit="-19.8"/>
                    <measurement group_id="O2" value="-7.7" lower_limit="-12.3" upper_limit="-3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on robust regression using M-estimation with terms for treatment, metformin strata (on or not on metformin), and baseline FPG value.</p_value_desc>
            <method>Robust regression</method>
            <param_type>Estimate difference</param_type>
            <param_value>-16.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.3</ci_lower_limit>
            <ci_upper_limit>-10.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin</title>
        <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin</title>
          <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
          <population>Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>Percent of glycosylated hemoglobin (A1C)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" lower_limit="-1.01" upper_limit="-0.71"/>
                    <measurement group_id="O2" value="-0.45" lower_limit="-0.60" upper_limit="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The ANCOVA model controlled for treatment and baseline A1C value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</title>
        <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</title>
          <description>A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.</description>
          <population>Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>Percent of glycosylated hemoglobin (A1C)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" lower_limit="-1.04" upper_limit="-0.67"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.24" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The ANCOVA model controlled for treatment and baseline A1C value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin</title>
        <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin</title>
          <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
          <population>Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.4" lower_limit="-43.4" upper_limit="-23.5"/>
                    <measurement group_id="O2" value="-6.2" lower_limit="-16.1" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on robust regression using M-estimation with terms for treatment and baseline 2-hr PMG value.</p_value_desc>
            <method>Robust regression</method>
            <param_type>Estimate difference</param_type>
            <param_value>-27.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.2</ci_lower_limit>
            <ci_upper_limit>-13.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</title>
        <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</title>
          <description>This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.</description>
          <population>Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.5" lower_limit="-62.9" upper_limit="-36.2"/>
                    <measurement group_id="O2" value="-11.9" lower_limit="-25.8" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The ANCOVA model controlled for treatment and baseline 2-hr PMG value.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-37.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.9</ci_lower_limit>
            <ci_upper_limit>-18.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin</title>
        <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin</title>
          <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
          <population>Full analysis set (on metformin) consists of all participants on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" lower_limit="-28.4" upper_limit="-16.0"/>
                    <measurement group_id="O2" value="-5.7" lower_limit="-11.9" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on robust regression using M-estimation with terms for treatment and baseline FPG value.</p_value_desc>
            <method>Robust Regression</method>
            <param_type>Estimate Difference</param_type>
            <param_value>-16.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.3</ci_lower_limit>
            <ci_upper_limit>-7.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</title>
        <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone</title>
          <description>This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.</description>
          <population>Full analysis set (not on metformin) consists of all participants not on metformin who received at least one dose of study drug, have a baseline measurement, and have at least one post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.3" lower_limit="-33.3" upper_limit="-19.4"/>
                    <measurement group_id="O2" value="-9.3" lower_limit="-16.3" upper_limit="-2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on robust regression using M-estimation with terms for treatment and baseline FPG value.</p_value_desc>
            <method>Robust Regression</method>
            <param_type>Estimate Difference</param_type>
            <param_value>-17.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.9</ci_lower_limit>
            <ci_upper_limit>-7.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced an Adverse Event</title>
        <description>An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.</description>
        <time_frame>Up to 26 weeks</time_frame>
        <population>All participants as treated population defined as all randomized participants who received at least one dose of study medication. Participants are included in the treatment group corresponding to the study treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Adverse Event</title>
          <description>An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.</description>
          <population>All participants as treated population defined as all randomized participants who received at least one dose of study medication. Participants are included in the treatment group corresponding to the study treatment actually received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Drug Due to an Adverse Event</title>
        <description>An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All participants as treated population defined as all randomized participants who received at least one dose of study medication. Participants are included in the treatment group corresponding to the study treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Drug Due to an Adverse Event</title>
          <description>An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.</description>
          <population>All participants as treated population defined as all randomized participants who received at least one dose of study medication. Participants are included in the treatment group corresponding to the study treatment actually received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 26 weeks (including 14 days following the last dose of study medication).</time_frame>
      <desc>All participants as treated population defined as all randomized participants who received at least one dose of study medication. Participants are included in the treatment group corresponding to the study treatment actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100 mg once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo once daily for 24 weeks. Participants continued pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="248"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="248"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="76" subjects_affected="35" subjects_at_risk="248"/>
                <counts group_id="E2" events="28" subjects_affected="17" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding the study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

